Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis.

Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis.

Gut (2013-12-18)

P Ferenci, G Dusheiko

材料

产品编号

品牌

产品描述

Sigma-Aldrich

利巴韦林, antiviral

利巴韦林, European Pharmacopoeia (EP) Reference Standard